Paris, October 30th, 2017at 8:00a.m. CET – ABIVAX (Euronext Paris: FR0012333284 – ABVX), an innovative biotechnology company targeting the immune system to eliminate viral and inflammatory diseases, as well as cancer, today announcesthat the senior management of ABIVAX will present a corporate development overview at the upcoming BIO-Europe® 2017 – 23rd Annual International Partnering Conference being held November 6-8, 2017 at the CityCube Berlin in Berlin, Germany.
The presentation of Prof. Hartmut Ehrlich, M.D., CEO of ABIVAX is scheduled on Tuesday, November 7th, 2:30pm CET in Room M6 on Level 3.
“This year already witnessed some exceptional milestones in the development of our product portfolio,” said Prof. Hartmut Ehrlich, M.D., CEO of ABIVAX. “In May, we reported first encouraging data from a phase IIa study (ABX464-004) with ABX464, a candidate with the potential to induce a functional cure in HIV patients. In particular, this study showed, for the very first time, that a therapeutic candidate could reduce HIV reservoirs in patients – an effect which was confirmed with a second phase IIa study (ABX464-005) in September. Based on also encouraging preclinical data on the molecule’s anti-inflammatory effect in the intestine, we expect to initiate patient recruitment for a proof-of-concept study with ABX464 (ABX464-101) in ulcerative colitis within the next couple of weeks. Moreover, in October we presented data of a preclinical proof-of-concept study showing that our immune enhancer ABX196 significantly increases therapeutic efficacy in oncology - a critical step towards a future partnership in immuno-oncology for ABIVAX. ABIVAX is experiencing an exciting time and I am very much looking forward to discuss our latest developments and achievements with industry experts and key opinion leaders at this important event.”
Companies interested in meeting with ABIVAX at BIO-Europe are requested to send an invitation through the event’s partneringONE®online system. In addition, the Company will also be available for media interviews and background discussions.
+ 33 6 64 18 99 59 or
+ 33 1 44 54 36 65
Standard: +33 1 53 83 08 41